Document Detail

Preeclampsia and pregnancy loss in women with a history of venous thromboembolism and prophylactic low-molecular-weight heparin (LMWH) during pregnancy.
MedLine Citation:
PMID:  16953268     Owner:  NLM     Status:  MEDLINE    
Limited data are available regarding complications of pregnancy and pregnancy outcome under prophylaxis with low-molecular-weight heparin (LMWH) in women with a history of thromboembolism (TE). We retrospectively evaluated pregnancy complications in a cohort of 80 women. All had a history of TE (76 venous, two arterial and two venous and arterial) and received prophylactic LMWH during 86 pregnancies. The rate of preeclampsia and stillbirth in these women was compared to that of a control group of 313 women without a history of TE and LMWH. Prophylaxis was started at a median of 10 weeks of gestation and usually continued until six weeks post partum. In 94% of the cases the outcome of pregnancy was favourable with a live birth. Four pregnancies (4.7%) ended in miscarriage. Two (2.3%) pregnancies were complicated by a thromboembolic event (one deep leg vein thrombosis and PRIND, respectively). One patient developed HELLP-syndrome. Severe preeclampsia occurred in three (3.8%) and stillbirth in one (1.3%) of the patients (n = 80), whereas this was the case in four (1.3%, odds ratio 3.01; 95% confidence interval (CI) 0.66-13.73, p = 0.15) and 10 (3.2%, OR = 0.38; 95% CI 0.05-3.04, p = 0.72) control women. Mean birth weight and standard deviation of infants was 3,160 +/- 930 g in patients and 3,300 +/- 540 g in controls (p = 0.11). We conclude that a favourable pregnancy outcome in women with a history of thromboembolism who use prophylactic LMWH during pregnancy can be expected. There was a trend towards a higher risk of preeclampsia, and these women should be carefully monitored for this complication.
Guelay Alguel; Rainer Vormittag; Ralph Simanek; Paul A Kyrle; Peter Quehenberger; Christine Mannhalter; Peter Husslein; Ingrid Pabinger
Related Documents :
12116608 - Anticoagulation during pregnancy.
25264288 - Validation of a triglyceride meter for use in pregnancy.
15222278 - Role of heparin in the antithrombotic treatment of valvulopathies.
22723978 - Placental pathology in pregnancies with maternally perceived decreased fetal movement--...
9583068 - Systemic lupus erythematosus and pregnancy.
20625758 - Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  96     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-09-05     Completed Date:  2007-01-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  285-9     Citation Subset:  IM    
Department of Internal Medicine I, Medical University Vienna, Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abortion, Spontaneous
Cohort Studies
Heparin, Low-Molecular-Weight / pharmacology*
Pre-Eclampsia / diagnosis*,  pathology*
Pregnancy Complications, Cardiovascular
Pregnancy Outcome
Retrospective Studies
Risk Factors
Thromboembolism / complications*
Venous Thrombosis / complications*
Reg. No./Substance:
0/Heparin, Low-Molecular-Weight

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Emerging anticoagulants for the treatment of venous thromboembolism.
Next Document:  Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation a...